EuroPCR 2026 – Prof Georg Nickenig (University Hospital Bonn, DE) joins us to discuss interim results from the TARGET study, evaluating the safety and performance of the Cardiovalve TR transcatheter tricuspid valve replacement system in patients with symptomatic tricuspid regurgitation.

The TARGET study is a multicentre, prospective, single-arm trial enrolling up to 100 patients across seven sites in Germany. Eligible patients have functional TR of grade 3 or above with NYHA Class II–IVa symptoms. The Cardiovalve system — comprising a valve and dedicated delivery system — is designed for transcatheter replacement of the tricuspid valve. Primary endpoints assess freedom from device- or procedure-related adverse events and TR grade reduction at 30 days, with follow-up extending to five years.

Interview Questions:

1. What is the current unmet need in managing severe tricuspid regurgitation, and how does transcatheter valve replacement fit into the treatment landscape?
2. What were the key objectives of the TARGET study, and what does the Cardiovalve TR system offer over existing approaches?
3. What can you tell us about the patient population enrolled, and what were the key eligibility considerations?
4. What are the interim safety and performance findings, and how do the 30-day outcomes compare to expectations?
5. What do the functional and quality-of-life data — including six-minute walk test and KCCQ scores — show at this stage?
6. What are the remaining challenges in achieving durable TR reduction with transcatheter replacement?
7. What do these interim results mean for the broader adoption of transcatheter tricuspid valve replacement in clinical practice?
8. What are the next steps for the TARGET study, and what questions remain to be answered?

Recorded onsite at EuroPCR 2026, Paris.
Editors: Jordan Rance
Videographer: Dan Brent
Support: This is an independent interview produced by Radcliffe Cardiology.